Genetic Testing à la Myriad

March 2012. Myriad Genetics’ offerings are contentious, in particularly when it comes to patent protection of genes – once in Europe, now in the U.S. In the exclusive interview with B2Bioworld, Peter Meldrum, CEO and co-founder of the Utah-based company describes expansion plans with biomarker services. He takes a stand on clinical DNA chips, and answers reproaches of patenting human genes, blocking scientific research, or pursuing a strangling licence policy for those laboratories willing to make breast cancer or colon carcinoma tests more widely available to patients. What will be Myriad’s future course, after Mr. Meldrum reaches retirement age.Reading time: 10 min

Read Now:
1,00 EUR (incl. 7% VAT)

Back to section